New and emerging data from clinical trials of statins

[1]  M. Hennerici,et al.  Design and Baseline Characteristics of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Study , 2003, Cerebrovascular Diseases.

[2]  I. Holme,et al.  Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial , 2003, The Lancet.

[3]  R. Collins,et al.  Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial , 2003, The Lancet.

[4]  Barry R. Davis,et al.  Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). , 2002, JAMA.

[5]  P. Macfarlane,et al.  Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial , 2002, The Lancet.

[6]  AndrewJ. S. Coats.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial , 2002, The Lancet.

[7]  P. Serruys,et al.  Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. , 2002, JAMA.

[8]  E. Braunwald,et al.  Design of the Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE IT)-TIMI 22 trial. , 2002, The American journal of cardiology.

[9]  M I Mackness,et al.  Design of the Collaborative AtoRvastatin Diabetes Study (CARDS) in patients with Type 2 diabetes , 2002, Diabetic medicine : a journal of the British Diabetic Association.

[10]  V. Athyros,et al.  Treatment with Atorvastatin to the National Cholesterol Educational Program Goal Versus 'Usual' Care in Secondary Coronary Heart Disease Prevention , 2002, Current medical research and opinion.

[11]  S. Yusuf.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Commentary , 2002 .

[12]  T. Meade.  Design and intermediate results of the Lower Extremity Arterial Disease Event Reduction (LEADER)* trial of bezafibrate in men with lower extremity arterial disease [ISRCTN41194621] , 2001, Current controlled trials in cardiovascular medicine.

[13]  Diabetes Atherosclerosis Intervention Study Investigators.  Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study , 2001, The Lancet.

[14]  A. Clayton,et al.  A pilot study with simvastatin and folic acid/vitamin B12 in preparation for the Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH). , 2000, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[15]  Bezafibrate Infarction Prevention study.  Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. , 2000, Circulation.

[16]  D. Hunninghake,et al.  Aggressive Lipid-Lowering Initiation Abates New Cardiac Events (ALLIANCE)-rationale and design of atorvastatin versus usual care in hypercholesterolemic patients with coronary artery disease. , 2000, The American journal of cardiology.

[17]  A. Hingorani,et al.  What is the optimal age for starting lipid lowering treatment? A mathematical model , 2000, BMJ : British Medical Journal.

[18]  B. Ansell.  Cholesterol, stroke risk, and stroke prevention , 2000, Current atherosclerosis reports.

[19]  J. Larosa,et al.  Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. , 1999, JAMA.

[20]  T. Wilt,et al.  Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. , 1999, The New England journal of medicine.

[21]  D. Waters,et al.  Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators. , 1999, The New England journal of medicine.

[22]  W. März,et al.  Rationale and design of a trial improving outcome of type 2 diabetics on hemodialysis , 1999 .

[23]  O. Faergeman,et al.  Effect of greater LDL-C reductions on prognosis-the incremental decrease in endpoints through aggressive lipid lowering (IDEAL) trial , 1999 .

[24]  T. Wilt,et al.  Rationale and design of the Arterial Disease Multiple Intervention Trial (ADMIT) pilot study. , 1999, The American journal of cardiology.

[25]  M. Ezekowitz,et al.  Rationale and design of the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) study that evaluates atorvastatin in unstable angina pectoris and in non-Q-wave acute myocardial infarction. , 1998, The American journal of cardiology.

[26]  J. Kjekshus,et al.  Effect of simvastatin on ischemic signs and symptoms in the Scandinavian simvastatin survival study (4S). , 1998, The American journal of cardiology.

[27]  C. Hennekens,et al.  Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials. , 1997, JAMA.

[28]  Post Coronary Artery Bypass Graft Trial Investigators.  The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. , 1997, The New England journal of medicine.

[29]  B. Davis,et al.  The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. , 1996, The New England journal of medicine.

[30]  J. Larosa.  Unresolved issues in early trials of cholesterol lowering. , 1995, The American journal of cardiology.

[31]  D. Gordon,et al.  Cholesterol Lowering in the Elderly: Results of the Cholesterol Reduction in Seniors Program (CRISP) Pilot Study , 1994 .